# Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer

> **NCT03461185** · PHASE2 · UNKNOWN · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 100 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** EGFR-TK Inhibitor
- **DRUG:** Anti-Angiogenic Drugs

## Key facts

- **NCT ID:** NCT03461185
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-01
- **Primary completion:** 2019-08-30
- **Final completion:** 2020-02-20
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2018-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03461185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03461185, "Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03461185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*